Welcome to our dedicated page for Wave Life Scienc news (Ticker: WVE), a resource for investors and traders seeking the latest updates and insights on Wave Life Scienc stock.
Wave Life Sciences Ltd. develops RNA medicines as a clinical-stage biotechnology company, using its PRISM platform to design oligonucleotides across RNA editing, RNA interference and antisense silencing. Company news commonly centers on clinical and regulatory updates for investigational programs such as WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, and WVE-007, an INHBE GalNAc-siRNA evaluated for obesity and cardiometabolic disease biology.
Updates also cover financial results, corporate presentations, platform expansion, collaboration activity involving PRISM, and governance or capital-structure matters. Recurring scientific disclosures include trial data presentations, safety and tolerability findings, regulatory engagement, and pipeline work in liver, muscle and neurologic diseases.
Wave Life Sciences (WVE) will participate in an analyst-led fireside chat at the Cantor 2026 Global Healthcare Conference in New York City on September 10, 2026 at 9:45 a.m. ET.
A live webcast and a time-limited replay will be available via the company’s Investor Events webpage.
Wave Life Sciences (NASDAQ: WVE) completed its redomiciliation, changing the parent company of the Wave group from a Singapore entity to a Delaware corporation through a scheme of arrangement under Section 210 of the Singapore Companies Act. The transaction was finalized after the close of trading on August 7, 2026 (Eastern Time), when all issued ordinary shares of Wave Life Sciences Ltd. were exchanged on a one-for-one basis for newly issued common shares of Wave Life Sciences, a Delaware corporation. According to Wave Life Sciences, its equity will continue to trade under the symbol “WVE”, with the new common stock beginning trading on NASDAQ on August 10, 2026, and the company does not anticipate any material impact on employees or day-to-day business.
Wave Life Sciences (NASDAQ: WVE) confirmed the expected completion timing of its previously announced redomiciliation from Singapore to the United States via a Scheme of Arrangement under Section 210 of the Singapore Companies Act. The company has already secured requisite shareholder approvals, and the High Court of the Republic of Singapore approved the Scheme on July 14, 2026 (Singapore Time).
The Redomiciliation is expected to become effective after the close of trading on Friday, August 7, 2026 (Eastern Time), when the court order is filed with Singapore’s Accounting and Corporate Regulatory Authority. According to Wave, it will then submit a series of related filings to the U.S. Securities and Exchange Commission after-market the same day.
Wave Life Sciences (Nasdaq: WVE) announced that President and CEO Paul Bolno will participate in analyst-led fireside chats at two August 2026 investor conferences: the BofA Securities 2026 SMID Cap Executive Insights Event on August 11 at 1:00 p.m. ET and the Canaccord Genuity 46th Annual Growth Conference on August 12 at 9:30 a.m. ET. Live webcasts and limited-time replays will be available via the Investor Events section of the company’s website.
Wave Life Sciences (Nasdaq: WVE) reported second quarter 2026 revenue of $2.3 million, down from $8.7 million a year earlier, and a net loss of $69.4 million versus $50.5 million. Research and development expenses were $51.3 million and general and administrative expenses were $24.8 million.
Cash, cash equivalents, and marketable securities totaled $490.6 million as of June 30, 2026, with an expected cash runway into the third quarter of 2028. Wave highlighted clinical progress, including Phase 2a multidose dosing underway in the INLIGHT trial for obesity candidate WVE-007, an FDA meeting scheduled for late summer 2026 on a potential accelerated approval pathway for AATD candidate WVE-006, and a planned 2H 2026 CTA filing for liver disease program WVE-008. Phase 2 combination and maintenance trials of WVE-007 are also planned to start in 2H 2026.
Wave Life Sciences (Nasdaq: WVE) will host a live webcast and conference call at 8:30 a.m. ET on Thursday, July 30, 2026, to review its second quarter 2026 financial results and provide business updates.
Investors can access the event via the “Investor Events” section of the company’s website, and an archived webcast will be available there following the live event.
Wave Life Sciences (NASDAQ: WVE) has secured shareholder approval for its proposed redomiciliation to the United States via a scheme of arrangement under Singapore’s Companies Act.
The Singapore High Court will hear the application to approve the scheme on July 14, 2026 at 2:30 pm (Singapore Time).
Wave Life Sciences (Nasdaq: WVE) has initiated the Phase 2a multidose portion of the INLIGHT trial of WVE-007, an investigational INHBE GalNAc-siRNA, in individuals with obesity and comorbidities.
Phase 1 single-dose data showed 14% visceral fat, 5% total fat, and 3% waist reductions at six months, with safety up to 600 mg and potential once or twice-yearly dosing. Phase 2a will assess body composition, weight, liver fat, HbA1c, and lipids over 12 months and is expected to inform development in obesity, MASH, type 2 diabetes, and cardiovascular disease, with additional Phase 2 trials planned for 2H 2026.
Eco Wave Power (NASDAQ: WAVE) reported that its onshore wave energy technology was featured for the second time in NVIDIA Founder and CEO Jensen Huang's GTC keynote, this time at GTC Taipei 2026.
The company is also progressing its planned pilot wave energy installation at Suao Port, Taiwan, after its local partner secured a land use agreement.
Wave Life Sciences (Nasdaq: WVE) announced participation in two June 2026 investor conferences.
- Jefferies Global Healthcare Conference: June 3, 2026, fireside chat at 10:30 a.m. ET.
- Goldman Sachs 47th Annual Global Healthcare Conference: June 8, 2026, fireside chat at 8:00 a.m. ET.
Live webcasts and limited-time replays will be available on Wave’s investor relations site under Investor Events.